Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) kicked off on Friday, up 7.73% from the previous trading day, before settling in for the closing price of $31.18. Over the past 52 weeks, RARE has traded in a range of $25.81-$50.00.
Annual sales at Healthcare sector company grew by 2.45% over the past five years. While this was happening, its average annual earnings per share was recorded 10.37%. With a float of $89.76 million, this company’s outstanding shares have now reached $96.27 million.
Ultragenyx Pharmaceutical Inc (RARE) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc is 6.96%, while institutional ownership is 99.94%. The most recent insider transaction that took place on Oct 13 ’25, was worth 250,252. In this transaction Chief Financial Officer of this company sold 7,942 shares at a rate of $31.51, taking the stock ownership to the 98,227 shares. Before that another transaction happened on Sep 18 ’25, when Company’s SVP, Chief Accounting Officer sold 64 for $29.17, making the entire transaction worth $1,867. This insider now owns 50,242 shares in total.
Ultragenyx Pharmaceutical Inc (RARE) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.39 earnings per share (EPS), lower than consensus estimate (set at -1.27) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.74% during the next five years compared to 2.45% growth over the previous five years of trading.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Trading Performance Indicators
Take a look at Ultragenyx Pharmaceutical Inc’s (RARE) current performance indicators. Last quarter, stock had a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.94, a number that is poised to hit -1.16 in the next quarter and is forecasted to reach -4.20 in one year’s time.
Technical Analysis of Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 53.95%.
During the past 100 days, Ultragenyx Pharmaceutical Inc’s (RARE) raw stochastic average was set at 46.98%, which indicates a significant decrease from 92.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.69 in the past 14 days, which was higher than the 1.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.75, while its 200-day Moving Average is $34.31. Nevertheless, the first resistance level for the watch stands at $34.50 in the near term. At $35.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $37.04. If the price goes on to break the first support level at $31.96, it is likely to go to the next support level at $30.34. Assuming the price breaks the second support level, the third support level stands at $29.42.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Key Stats
The company with the Market Capitalisation of 3.24 billion has total of 96,478K Shares Outstanding. Its annual sales at the moment are 560,230 K in contrast with the sum of -569,180 K annual income. Company’s last quarter sales were recorded 159,930 K and last quarter income was -180,410 K.
